No Data
Biomea Fusion Initiated at Overweight by Capital One
Biomea Fusion's BMF-219: A Catalyst for Growth in Metabolic Disease Treatment and Oncology
Capital One Financial Initiates Biomea Fusion(BMEA.US) With Buy Rating, Announces Target Price $25
Citi Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $22
Positive Week for Biomea Fusion, Inc. (NASDAQ:BMEA) Institutional Investors Who Lost 53% Over the Past Year
With 51% Institutional Ownership, Biomea Fusion, Inc. (NASDAQ:BMEA) Is a Favorite Amongst the Big Guns